CDCP1 and colorectal carcinoma: Importantly, inhibiting the SMYD3/CDCP1/Src axis deactivates CAFs, curbs hepatic metastatic outgrowth, and sensitizes tumors to oxaliplatin, nominating this pathway as a clinically actionable vulnerability in CRC.